Brean Capital said $PGNX MIP 1095 shows clear utility in advanced mCRPC, according to recent clinical studies. Shares are Buy rated & PT $11
ANSYS beats by $0.10, reports revs in-line; guides Q1 EPS in-line, revs in-line; guides FY14 EPS in-line, revs in-line (ANSS) : Reports Q4 (Dec) earnings of $0.96 per share, excluding non-recurring items, $0.10 better than the Capital IQ Consensus Estimate of $0.86; revenues rose 5.4% year/year to $236.7 mln vs the $237.17 mln consensus. Co issues in-line guidance for Q1, sees EPS of $0.73-0.76, excluding non-recurring items, vs. $0.76 Capital IQ Consensus Estimate; sees Q1 revs of $212-220 mln vs. $217.44 mln Capital IQ Consensus Estimate. Co issues in-line guidance for FY14, sees EPS of $3.25-3.37, excluding non-recurring items, vs. $3.32 Capital IQ Consensus Estimate; sees FY14 revs of $939-969 mln vs. $949.02 mln Capital IQ Consensus Estimate.
It is common practice to adjust new laws being implemented. Only in Fox newsworld and when a Dem is in the White House is it an "outrage". And this adjustment helps businesses, another point overlooked by the right wing anything Obama does is wrong types.
CEO Baker suffered a ski accident that incapacitated him to come to the y BIO CEOconf.